It is my great pleasure to invite you to The European Congress on Controversies in Lymphoma (Lymphoma2020), taking place on 23-24 April 2020 in Vienna, Austria.
The past few years have witnessed significant improvements in our understanding of lymphoproliferative malignancies and in our capabilities to treat patients diagnosed with these diseases. The introduction of new agents, including small molecules, non-conjugated and conjugated antibodies, and immunomodulation technologies (particularly chimeric antigen receptor T cells) has considerably changed the landscape of lymphoproliferative malignancies, with most patients achieving at least a durable response and even cure.
BEST ABSTRACT AWARD
We look forward to hearing from you.